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Abstract 
Background: Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, PDGFRA 
mutation or WT for KIT and PDGFRA have a worse progression‑free survival (PFS) compared to patients with KIT exon 
11 mutated tumors. We evaluated the immunohistochemical (IHC) expression of p‑IGF1R (Y1316) and MMP3 as pre‑
dictors of PFS or overall survival (OS).
Methods: Ninety‑two advanced GIST patients included in GEIS‑16 study with KIT and PDGFRA mutational informa‑
tion were examined for p‑IGF1R (Y1316) and MMP3 expression in a tissue micro‑array. To study activation of the IGF1R 
system, we have used an antibody (anti‑pY1316) that specifically recognizes the active phosphorylated form of the 
IGF1R. DNA was extracted from paraffin‑embedded tissues and intronic PCR primers were used to amplify exons 9, 11, 
13 and 17 of KIT, 12 and 18 of PDGFRA. Bidirectional sequencing with specific primers was performed on a ABI3100 
sequencer using the Big Dye Terminator v3.1 kit. Multivariate model was built using a stepwise automated variable 
selection approach with criterion to enter the variable in the model of p < 0.10 and criterion to keep the variable in 
the model of p < 0.05. PFS was computed as the date of imatinib initiation to progression or death. Overall survival 
was defined as the time from imatinib initiation to death.
Results: Phospho‑IGF1R was expressed only in 9 % (2/22) of cases without KIT mutation. MMP3 expression was 
detected in 2/5 patients (40 %) with PDGFRA mutation, 1/16 patients (6 %) with WT genotype and 7/71 patients 
(10 %) of KIT mutant patients. At univariate analysis KIT exon 11/13 mutation had better PFS than patients with exon 
9 mutation, PDGFRA mutation or WT genotype (p = 0.021; HR: 0.46; 95 %CI (0.28–0.76). Less than 24 months disease 
free‑interval (HR 24.2, 95 % CI 10.5–55.8), poor performance status (PS) (HR 6.3, 95 % CI 2.5–15.9), extension of disease; 
>1 organ (HR 1.89; 95 % CI 1.03–3.4) and genotype analysis (HR 0.57, 95 % CI 0.37–0.97) but not immunophenotype 
analysis (HR 1.53; 95 % CI 0.76–3.06) were the strongest prognostic factors for PFS in the multivariate analysis.
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Background
Gastrointestinal stromal tumour (GIST) is the most 
common sarcoma of the gastrointestinal tract. Imatinib 
mesylate (IM), a receptor tyrosine-kinase (RTK) inhibitor 
active against KIT and PDGFRA, is the standard treat-
ment for advanced GIST patients [1, 2]. Mutations in the 
KIT and PDGFRA oncogenes are identified in 85–90  % 
of patients with advanced GIST. Most mutations in 
advanced GIST are located in KIT exon 11 (68–75 %) but 
also in exons 9 (8–15 %), 13 and 17 (1 %) and PDGFRA 
homologous exons (2–4 %) [2–4].
A small subgroup of GIST patients (10–15  %) shows 
primary IM resistance (i.e. disease progression in the 
first 6 months of IM treatment). Unfortunately, 70–80 % 
of IM-sensitive patients acquire secondary resistance 
due to new IM-resistant KIT or PDGFRA mutations and 
KIT amplification [5]. Mutational analysis of these genes 
affects prognosis and responsiveness to tyrosine kinase 
inhibitors [2]. D842V PDGFRA (1 %) and RAS and BRAF 
(≤5  % of GIST) mutations, predicts primary IM resist-
ance [6, 7].
Insulin-growth factor 1 receptor (IGF1R) is expressed 
in GIST patients [8, 9]. About 20–40  % of KIT/PDG-
FRA WT GIST patients show loss of function of the 
succinate dehydrogenase (SDH) including A, B, C, D 
complex which is associated to IGF1R expression [10, 
11]. Although IGF1R expression is associated with a WT 
genotype, a very small subset of GIST SDHB-positive 
patients with mutations in KIT or PDGFRA (<1  % of 
all GIST) can also express IGF1R [11]. Recently IGF1R 
expression was found to be associated to lower response 
in advanced GIST but without affecting progression free 
survival or overall survival (OS) [12]. However, no pre-
vious studies have correlate IM efficacy and the activa-
tion of IGF1R (phospho-IGF1R). This aspect is important 
because phospho-IGF1R (p-IGF1R) expression does not 
correlate well with overall IGF1R expression [8]. MMP3 
has been shown to be over-expressed (33-fold change) 
in a GIST-resistant (GIST882-R) cell line compared with 
the parental sensitive line [13].
Because p-IGF1R induce PI3K-AKT pathway activation 
and MMP3 can directly induce epithelial-mesenchymal 
transition [14], a widely known mechanisms of chemo-
therapy-resistance, we hypothesize that GIST patients 
with positive immunophenotype (either p-IGF-1R posi-
tive or MMP7 positive) can contribute to IM resistance. 
We selected patients with available tissue for biological 
analysis, from a cohort of advanced GIST patients treated 
with IM in 12 Spanish institutions included in the GEIS-
16 study. The GEIS-16 study was a retrospective study to 
evaluate the role of metastatic surgical resection in GIST 
patients, sensitive to IM therapy [15].
Patients and methods
Study design
We selected patients from a cohort of advanced GIST 
patients treated with IM from January 2001 to December 
2008 in 16 Spanish institutions included in the GEIS-16 
study. Four institutions that participated in the GEIS-
16 study did not participate in the GEIS-19 study. Only 
patients with available tissue for genotype and immu-
nophenotype analysis were selected for the GEIS-19 
study. Response rate was evaluated following RECIST 
criteria. The last patient status update was done in June 
2015.
Mutational analysis
DNA was isolated from 3 to 20  μm FFPET sections. 
After deparaffinization, DNA was extracted using the 
QIAamp® DNA FFPE Tissue kit (Qiagen, Valencia, CA, 
USA) following the manufacturer’s instructions. Amplifi-
cation of exons 9, 11, 13 and 17 of KIT and exons 12 and 
18 of PDGFRA was carried out as previously described 
[14, 15]. Ten microliters of PCR products were visualized 
in ethidium-bromide-stained 2  % UltraPure agarose gel 
(Life Technologies, Paisley, Scotland) and photographed. 
Negative controls were included in each set of amplifi-
cations. Bidirectional sequencing with specific primers 
was performed on an AB I3130xL sequencer using the 
Big Dye Terminator v3.1 kit (Applied Biosystems, Inc, 
Foster City, CA). Sequencing analysis, version 5.2 soft-
ware (Applied Biosystems) and the National Center for 
Bioinformatics Information blast tool (http://www.ncbi.
nlm.nih.gov/BLAST/) were used to confirm the mutation 
sequences for KIT (ENSG00000157404) and PDGFRA 
(ENSG00000134853).
Tissue microarray
Formalin-fixed paraffin embedded tissue samples of 
representative tumor regions from primary GISTs 
were collected for the preparation of 3 tissue micro-
arrays. Briefly, three tissue cylinders with a diameter 
of 1.0  mm were punched out from morphologically 
representative areas of each donor tissue block and 
brought into a recipient paraffin block using a manual 
tissue arrayer.
Conclusions: Our results do not support p‑IGF‑1R and MMP3 evaluation in non‑selected GIST patients but evalua‑
tion of this immunophenotype in WT and mutant PDGFR mutation in larger group of GIST patients, deserve merits.
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Immunohistochemistry and scoring
To study activation of the IGF1R system, we have used 
a primary antibody (anti-pY1316) that specifically rec-
ognizes the phosphorylated (active) form of the IGF1R 
(Generous gift of Dr. Rubini, Ferrara, Italy). Briefly, paraf-
fin-embedded sections were deparaffinized in xylene and 
rehydrated in downgraded alcohols and distilled water. 
Heat-induced epitope retrieval and a high-pH buffer (for 
anti-p-IGF1R) and citrate buffer pH6 (for anti-MMP3) 
(both buffers from Ventana Medical Systems, Tucson, 
AR) were applied for 30  min before the primary anti-
body. Then, tissue microarrays were incubated with anti-
pY1316 antibody (dilution 1/50), and with an anti-MMP3 
antibody (Abcam #ab137659; dilution 1/50), followed by 
a specific secondary antibody using the DAB Map detec-
tion kit (Ventana Medical Systems, Tucson, AR). Sections 
were counterstained with hematoxylin and analyzed by 
light microscopy. Cases were scored as positive or nega-
tive. Cases were scored as positive when at least 1 % of 
cells showed cytoplasmic expression of the molecule 
under study (either p-IGF1R, or MMP3).
Statistical analysis
Proportions are compared using Chi square test or Fish-
er’s test when appropriate. Means are compared using t 
test. Survival analyses are done using Kaplan–Meier esti-
mates and Cox proportional hazards model. Progression-
free survival is defined as the time from the date Imatinib 
was started to the date of progression or death which-
ever occurred first. Overall survival is defined as the time 
from the date Imatinib was started to the date of death. 
Multivariate models are built using two approaches: (1) 
Entering all the variables in the model. (2) Using a step-
wise automated variable selection approach with crite-
rion to enter the variable in the model of p  <  0.10 and 
criterion to keep the variable in the model of p < 0.05.
Results
Among 190 patients evaluated in the GEIS-16 study, 
19 showed primary IM resistance (10  %). Paraffin-
embedded tissue from primary tumours, were obtained 
from 92 untreated advanced GIST patients (46 % of the 
whole cohort of patients) for mutational analysis and 
tissue microarray construction (TMAs) in twelve Span-
ish Institutions. Eighty-eight patients were treated with 
400  mg/day and 4 patients included in EORTC-ISG-
AGITG phase III trial received 800  mg/day. Among 92 
patients evaluated in GEIS-19 study 9 patients show pri-
mary IM resistance (10 %). Baseline characteristics of the 
patients according the immunophenotype are shown in 
Table 1. Seventy-one patients (78 %) had KIT mutations, 
5 patients (5 %) had PDGFRA mutations and 16 patients 
(17 %) were WT for KIT and PDGFRA. Phospho-IGF1R 
was expressed only in 9  % (2/21) of cases without KIT 
mutation. MMP3 was expressed in 10 % of cases. MMP3 
expression was detected in 2/5 patients (40 %) with PDG-
FRA mutation, 1/16 patients (6  %) with WT genotype 
and 7/71 patients (10  %) of KIT mutant patients. Posi-
tive immunophenotype, was mostly observed in WT and 
PDGFR genotypes (p  =  0.006). Representative cases of 
p-IGF1R and MMP3 expression are shown in Fig. 1.
Patients with mutations in KIT exon 11/13 showed 
higher response rate to IM (77  %) than patients with 
mutations in KIT exon 9 (25 %), PDGFRA (0 %) or wild-
type (53  %) genotype (p  <  0.0001). Response rate was 
observed in 4/11 (36 %) patients with MMP3 or p-IGF1R 
expression (1 patient was non-evaluable for response) 
vs 56/78 (71  %) in GIST patients without MMP3 or 
p-IGF1R expression (2 patients were non-evaluable for 
response) (p =  0.025). At univariate analysis KIT exons 
11/13 had better PFS than patients with exon 9, PDGFRA 
mutation or WT genotype [p  =  0.037; HR: 0.57; (95  % 
CI 0.33–0.97)]. Patients with MMP3 or p-IGF1R expres-
sion have non-significant poor PFS [14.1 months 95 % CI 







Female 33 (41 %) 8 (66 %) 0.13
Mean age (SD) 60.7 (18.8) 65.1 (12.3) 0.20
Metastatic status 0.8
 1 site 61 (76 %) 10 (83 %)
 >1 site 19 (24 %) 2 (17 %)
Primary site 0.4
 Stomach 30 (37) 5 (42)
 Small bowel 33 (41) 2 (16)
 Other 17 (22) 5 (42)
KIT/PDGFR status 0.006
 KIT mutation 64 (79 %) 7 (58 %)
 PDGFR 2 (3 %) 3 (25 %)
 WT 14 (18 %) 2 (17 %)
ECOG PS 0.79
 0–1 72 (90 %) 11 (92 %)
 2 8 (10 %) 1 (8 %)
Liver metastasis 48 (60 %) 7 (58 %) 0.91
Surgery of primary 74 (92 %) 11 (92 %) 0.91
Disease free interval
 <24 months 20 (25 %) 4 (33 %) 0.5
 >24 months 60 (75 %) 8 (67 %)
 Mean LDH (SD) 332.1 (160.8) 482.4 (429.8) 0.39
 Mean leucocytes 
(SD)
7.1 (3) 8.1 (5.1) 0.56
 Mean albumin 
(SD)
40.9 (7.1) 39.6 (6.1) 0.62
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(0–29.8)] than patients without either p-IGF1R or MMP3 
expression [37.1 months 95 % CI (25.3–48.9)] (p = 0.33) 
(Fig.  2a. Disease free-interval, performance status (PS), 
extension of disease and genotype but not immunophe-
notype (p-IGF1R or MMP3) were the strongest prog-
nostic factors for PFS in the multivariate analysis. There 
were also no differences in survival according MMP3 
or p-IGF1R expression (Fig.  2b). For OS only perfor-
mance status, disease free-interval, surgery of primary 
tumor and number of metastatic sites remain significant 
(Table 2).
Discussion
Our main findings reveal that, the proposed immunophe-
notype (p-IGF1R or MMP3 positive) correlates with poor 
response rate and a worse but statistically non-significant 
progression-free survival, after adjustment of all critical 
variables in the multivariate analysis.
IGF1R is expressed in a subset of GIST patients with-
out KIT and PDGFRA mutations [10, 11]. We have 
confirmed that IGF1R activation is a rare event in KIT 
mutant patients but, although with a low frequency, this 
receptor is activated in GIST patients carrying PDGFRA 
mutations or WT genotype. MMP3 is expressed in less 
Fig. 1 a Mild expression of MMP‑3 is present in the cytoplasm 
of tumor cells, especially those with a higher degree of anaplasia. 
(×200) b Expression of p‑IGF1R was seen in tumoral cells. (×400)  
c Expression of p‑IGF1R was seen in tumoral cells. (×200)
Fig. 2 Cumulative survival curves for patients according MMP3/p‑
IGF‑1R expression. a Progression‑free survival. Log‑rank test, 1.39, 
p = 0.34. b Overall survival. Log‑rank test, 1.53, p = 0.23
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than 10 % of KIT mutant and WT genotype in advanced 
GIST patients and in 40 % of PDGFRA mutant patients 
[16]. Although our data is limited to five patients, it 
could have clinical implications, because new drugs with 
potential activity in PDGFRA patients such as crenolanib 
[17] could be inactive in PDGFRA mutant patients that 
express MMP3.
We are tempted to speculate that in a small subset of 
patients with GIST with KIT mutations (10  %) and an 
important subset of WT genotype and PDGFRA muta-
tions (21  %) our proposed immunophenotype bypass 
KIT signaling. It has been previously published that 
GIST patients with KIT mutation express p-STAT3 and 
p-AKT more intensely than patients with PDGFRA 
mutation [18]. Because MMP3 thought RAC1b can acti-
vate NF-kB and cyclin D1 but not AKT and STAT3 [19] 
and IGF1R not only activates AKT but also MEK/ERK 
pathway, our proposed immunophenotype may confer 
KIT-independent IM resistance, specially, in the subset of 
WT or PDGFR mutant GIST patients.
Our study has several limitations. First the data comes 
from a retrospective cohort of patients and therefore PFS 
are more subject to investigator interpretation. Second, 
the phenotype implicates only 12  % of all the analyzed 
GIST patients. Third our cohort included a limited num-
ber of patients. Four, the percentage of WT KIT/PDGFR 
patients is slightly higher than in other published series. 
We cannot rule out that other more sensitive methods 
such as high-resolution melting analysis, could decrease 
the number of WT GIST patients. Finally, other RTK 
such as MET or FGFR3 that has been implicated recently 
in primary and secondary IM resistance, has not been 
evaluated [20, 21]. Despite of it, the multicenter nature of 
the study and the long follow-up (that include the geno-
type and all the important clinical variables) supports the 
strength of our conclusions.
Table 2 Univariate and multivariate analysis
Univariate (PFS) Univariate (OS) Multivariate (PFS) Multivariate (OS)
HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value
Group
 MMP3 and pIGF1R− Reference Reference Reference Reference
 MMP3 or pIGF1R+ 1.39 (0.71–2.72) 0.34 1.10 (0.52–2.17) 0.95 1.53 (0.76–3.06) 0.23 1.67 (0.77–3.65) 0.20
 Albumin >median 0.73 (0.44–1.23) 0.24 0.82 (0.47–1.44) 0.49
 Leucocytes >median 1.16 (0.73–1.85) 0.53 1.50 (0.90–2.49) 0.12
 LDH >median 1.36 (0.84–2.21) 0.21 1.50 (0.89–2.55) 0.13
 Age 0.99 (0.97–1.00) 0.33 0.99 (0.98–1.01) 0.51
Kit mutation
 Exon 11/13 0.46 (0.28–0.76) 0.021 0.71 (0.41–1.21) 0.21 0.57 (0.33–0.97) 0.037
 Other Reference Reference
ECOG
 PS 0 Reference Reference Reference Reference
 PS 1 1.13 (0.67–1.8) 0.65 1.17 (0.66–2.07) 0.59 1.74 (0.99–3.07) 0.055 2.00 (1.08–3.67) 0.026
 PS > 1 1.64 (0.73–3.68) 0.23 2.05 (0.88–4.76) 0.095 4.45 (1.85–10.76) 0.0009 5.25 (2.08–13.26) 0.0005
 Female 1.02 (0.64–1.63) 0.92 1.01 (0.61–1.67) 0.96
Primary site
 Stomach 1.61 (1.00–2.59) 0.050 1.36 (0.82–2.27) 0.24
 Others Reference Reference
Extension of disease Ta
 1 metastatic organ Reference Reference Reference Reference
 2 or more metastatic 
organs
2.59 (1.52–4.42) 0.0005 2.56 (1.46–4.52) 0.0011 1.84 (1.03–3.27) 0.039 1.93 (1.03–3.62) 0.041
Surgery primary tumor
 Yes Reference Reference
 No 1.19 (0.51–2.75) 0.75 (0.27–2.08) 0.59 0.26 (0.09–0.76) 0.014
Disease‑free interval 0.69
 <24 months 13.4 (6.93–25.77) <0.0001 6.61 (3.72–11.79) <0.0001 18.87 (8.54–41.73) <0.0001 16.73 (7.97–35.13) <0.0001
 ≥24 months Reference Reference Reference Reference
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